S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Something is Coming for America's Top Stock (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
66,000% upside on tiny biotech? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Something is Coming for America's Top Stock (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
66,000% upside on tiny biotech? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Something is Coming for America's Top Stock (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
66,000% upside on tiny biotech? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Something is Coming for America's Top Stock (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
66,000% upside on tiny biotech? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
NASDAQ:SANA

Sana Biotechnology (SANA) Stock Forecast, Price & News

$3.58
-0.29 (-7.49%)
(As of 10/2/2023 ET)
Compare
Today's Range
$3.51
$3.86
50-Day Range
$3.58
$5.94
52-Week Range
$2.99
$8.01
Volume
1.29 million shs
Average Volume
1.13 million shs
Market Capitalization
$705.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.40

Sana Biotechnology MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
162.6% Upside
$9.40 Price Target
Short Interest
Bearish
22.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Sana Biotechnology in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.57) to ($1.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

569th out of 975 stocks

Biological Products, Except Diagnostic Industry

84th out of 157 stocks


SANA stock logo

About Sana Biotechnology (NASDAQ:SANA) Stock

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.

SANA Price History

SANA Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Sana Biotechnology (NASDAQ:SANA) Shares Down 3.3%
Sana Biotechnology falls after pipeline updates
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Sana Biotechnology (SANA) Initiated with a Buy at Citi
See More Headlines
Receive SANA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

SANA Company Calendar

Last Earnings
8/03/2023
Today
10/03/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SANA
Fax
N/A
Employees
424
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.40
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+162.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-269,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.62 per share

Miscellaneous

Free Float
128,209,000
Market Cap
$705.05 million
Optionable
Not Optionable
Beta
0.84
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Steven D. Harr M.D. (Age 53)
    Pres, CEO & Director
    Comp: $1.04M
  • Dr. Richard C. Mulligan Ph.D. (Age 68)
    Exec. Vice Chairman & Head of SanaX
  • Mr. Bernard J. Cassidy J.D. (Age 68)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $491.39k
  • Mr. Nathan Hardy M.B.A. (Age 47)
    Exec. VP & CFO
  • Brittany Mccleery
    Accounting Mang.
  • Dr. Edward Rebar Ph.D. (Age 55)
    Sr. VP & CTO
  • Ms. Robin Andrulevich (Age 57)
    Exec. VP & Chief People Officer
  • Mr. Paul Brunetta M.D.
    Sr. VP and Head of Clinical & Translational Science
  • Mr. Christian  Hordo M.B.A.Mr. Christian Hordo M.B.A. (Age 40)
    Exec. VP & Chief Bus. Officer
  • Dr. Sonja Schrepfer M.D. (Age 48)
    Ph.D., Sr. VP & Head of Hypoimmune Platform













SANA Stock - Frequently Asked Questions

Should I buy or sell Sana Biotechnology stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SANA shares.
View SANA analyst ratings
or view top-rated stocks.

What is Sana Biotechnology's stock price forecast for 2023?

6 analysts have issued twelve-month price objectives for Sana Biotechnology's stock. Their SANA share price forecasts range from $6.00 to $13.00. On average, they expect the company's stock price to reach $9.40 in the next year. This suggests a possible upside of 162.6% from the stock's current price.
View analysts price targets for SANA
or view top-rated stocks among Wall Street analysts.

How have SANA shares performed in 2023?

Sana Biotechnology's stock was trading at $3.95 at the beginning of 2023. Since then, SANA shares have decreased by 9.4% and is now trading at $3.58.
View the best growth stocks for 2023 here
.

When is Sana Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our SANA earnings forecast
.

How were Sana Biotechnology's earnings last quarter?

Sana Biotechnology, Inc. (NASDAQ:SANA) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.03.

What ETFs hold Sana Biotechnology's stock?

ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).IQ U.S. Small Cap ETF (CSML).

When did Sana Biotechnology IPO?

(SANA) raised $322 million in an initial public offering on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities served as the underwriters for the IPO.

What is Sana Biotechnology's stock symbol?

Sana Biotechnology trades on the NASDAQ under the ticker symbol "SANA."

How do I buy shares of Sana Biotechnology?

Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sana Biotechnology's stock price today?

One share of SANA stock can currently be purchased for approximately $3.58.

How much money does Sana Biotechnology make?

Sana Biotechnology (NASDAQ:SANA) has a market capitalization of $705.05 million. The company earns $-269,480,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

How many employees does Sana Biotechnology have?

The company employs 424 workers across the globe.

How can I contact Sana Biotechnology?

Sana Biotechnology's mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The official website for the company is sana.com. The company can be reached via phone at 206-701-7914 or via email at investor.relations@sana.com.

This page (NASDAQ:SANA) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -